On March 16, 2026, the U.S. Food and Drug Administration (FDA) issued a Class II recall for nearly 90,000 bottles of Children's Ibuprofen Oral Suspension, USP (100 mg per 5 mL) in 4 fl oz (120 mL) packaging.
The Recall: Affected Product Details and Distribution
Children's ibuprofen recalled by the FDA is a berry-flavored solution recommended for children ages 2 to 11. The recall targets bottles with lot numbers 7261973A and 7261974A, which expire on January 31, 2027. The recall number is D-0390-2026.
The affected ibuprofen was manufactured in India and distributed across the U.S. by Strides Pharma Inc. Strides Pharma's website provides additional product details.
Foreign Substance Contamination and Health Risks
The recall was initiated due to complaints of "black particles" and a "gel-like mass" found in some bottles. The FDA classified this as a Class II recall, indicating the potential for temporary or medically reversible adverse health consequences. The presence of an unknown foreign substance in a medication intended for children raises significant health concerns.
The FDA has not yet provided a detailed analysis of the foreign substance. However, the recall underscores the importance of vigilance in the pharmaceutical supply chain to prevent such incidents.
“The primary goal is to ensure the safety of our children. This recall is a stark reminder of the rigorous quality control measures required in pharmaceutical manufacturing.”
— Dr. Emily Hart, Pediatrician and Public Health Advocate
The Next Steps for Parents and Consumers
The FDA's enforcement report details the recall and urges consumers to check their medication against the listed lot numbers. Parents and caregivers should immediately stop using any children's ibuprofen with the affected lot numbers and contact Strides Pharma Inc for further instructions.
This is the latest ibuprofen recall in 2026, and the FDA continues to monitor the situation closely. The agency's proactive approach aims to mitigate potential health risks and ensure public safety.
On March 20, 2026, the FDA will hold a press conference to discuss the children's ibuprofen recall and the steps being taken to address the issue. The public is encouraged to stay informed and follow updates from the FDA for the latest developments in this ongoing situation.
